<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597867</url>
  </required_header>
  <id_info>
    <org_study_id>02/2017</org_study_id>
    <nct_id>NCT03597867</nct_id>
  </id_info>
  <brief_title>PGE2 Levels in Patient Treated With NSAIDs</brief_title>
  <official_title>Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Trieste</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine vitreous levels of nonsteroidal antinflammatory drugs
      (NSAIDs) and prostaglandinE2 (PGE2) in eyes scheduled for vitrectomy.

      All patients received the study drugs for 3 days before surgery. 0.5 to 1.0 mL of undiluted
      vitreous was removed using the vitreous cutter positioned in the midvitreous cavity. Samples
      were immediately frozen and stored at −80°C until analysis.

      Sample analyses were performed using an high-performance liquid chromatography system. The
      lower limit of quantitation was 0.8 ng/mL.

      PGE2 levels were analyzed using the Prostaglandin E2 Monoclonal EIA Kit (Cayman Chemical
      Company) according to the manufacturer's instructions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Actual">July 9, 2018</completion_date>
  <primary_completion_date type="Actual">July 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitreous NSAIDs and PGE2 levels</measure>
    <time_frame>3 days after topical NSAID administration</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dicloftil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Na 0.1% Oph Soln, &quot;Dicloftil®&quot;, NSAID eyedrops administered three days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevanac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac 0.3% Ophthalmic Suspension, &quot;Nevanac 3mg/ml®&quot;, NSAID eyedrops administered three days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin 5 MG/ML Ophthalmic Suspension, &quot;Indom ®&quot;, NSAID eyedrops administered three days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yellox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromfenac 0.09 % Ophthalmic Solution, &quot;Yellox®&quot;, NSAID eyedrops administered three days before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Artificial tears for 3 days preoperatively</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dicloftil</intervention_name>
    <description>Dosing of drug 3 days prior to surgery</description>
    <arm_group_label>Dicloftil</arm_group_label>
    <other_name>Diclofenac Na 0.1% Oph Soln</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevanac</intervention_name>
    <description>Dosing of drug 3 days prior to surgery</description>
    <arm_group_label>Nevanac</arm_group_label>
    <other_name>Nepafenac 0.3% Ophthalmic Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indom</intervention_name>
    <description>Dosing of drug 3 days prior to surgery</description>
    <arm_group_label>Indom</arm_group_label>
    <other_name>Indomethacin 5 MG/ML Ophthalmic Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yellox</intervention_name>
    <description>Dosing of drug 3 days prior to surgery</description>
    <arm_group_label>Yellox</arm_group_label>
    <other_name>Bromfenac 0.09 % Ophthalmic Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  epiretinal membrane or full thickness macular hole scheduled for vitrectomy

        Exclusion Criteria:

          -  vitreous hemorrhage

          -  diabetes

          -  glaucoma

          -  concurrent retinovascular disease

          -  previous ocular inflammation

          -  previous ocular surgery

          -  history of ocular trauma

          -  previuos intravitreal injections

          -  concomitant intake of topical or systemic NSAIDs or corticosteroid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco R Pastore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste Trieste, TS, 34129, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 21, 2018</last_update_submitted>
  <last_update_submitted_qc>July 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Trieste</investigator_affiliation>
    <investigator_full_name>Marco Rocco Pastore</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitreoretinal surgery</keyword>
  <keyword>epiretinal membrane</keyword>
  <keyword>macular hole</keyword>
  <keyword>non steroidal antinflammatory drugs</keyword>
  <keyword>prostaglandin E2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

